Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a buy rating to a hold rating in a research note released on Saturday morning.

KNSA has been the subject of several other research reports. Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.29.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA opened at $46.50 on Friday. The firm has a 50 day simple moving average of $43.94 and a 200-day simple moving average of $40.86. Kiniksa Pharmaceuticals International has a one year low of $18.25 and a one year high of $49.12. The firm has a market cap of $3.56 billion, a price-to-earnings ratio of 62.84 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) earnings per share. Equities analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Barry D. Quart sold 2,690 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $564,570. This represents a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,605 shares of company stock worth $2,122,646 over the last 90 days. Company insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter worth approximately $31,000. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter valued at approximately $32,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.